BeOne Medicines Ltd. ADR (ONC)

NASDAQ: ONCHealth CareBiotechnology: Pharmaceutical PreparationsUSD

364.02+1.24 (+0.34%)

At close: Oct 7, 4:00 PM ET · Delayed 15 min

ONC stock chart

Technical analysis

Key statistics

All statistics

Market cap: $41.41B
P/E (TTM): 65.12
Forward P/E: 35.49
EPS (TTM): $5.59
Dividend yield: None
Ex-dividend date: —
52-week range: 253.95 – 385.22
Day range: 359.57 – 367.57
Volume / Avg: 137.23K / 391.40K
Beta: —
Shares outstanding: 104.92M
Next earnings: Nov 5, 2026

52-week range

$253.95$385.22

ONC stock today

Shares of BeOne Medicines (ONC) finished higher on Oct 7 at $364.02, a gain of 0.34% or $1.24 per share, versus the S&P 500's 0.22% decline. Trading was light, with 137.23K shares changing hands, about 35% of the average daily volume. At this level, ONC sits near the top of its 52-week range of $253.95 to $385.22: 5.5% below the high, set on Nov 17, 2025 and 43.3% above the low.

ONC is up 19.8% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 6.6%. At 65.1x trailing earnings, BeOne Medicines trades above the peer-group median of 29.9x. Its forward P/E of 35.5x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. BeOne Medicines's next earnings report is expected on Nov 5, 2026.

Summary generated from market data by MetaCap's automated system. Methodology

About BeOne Medicines

Company profile

BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK targeting chimeric degradation activation compound active against wild type and mutant BTK; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187 and BG-C0902, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC.

Sector: Health Care
Industry: Biotechnology: Pharmaceutical Preparations
CEO: Mr. John V. Oyler
Headquarters: Basel
Employees: 12,000
IPO year: 2016
Website: beonemedicines.com

Financial highlights

Full financials

In fiscal 2025, BeOne Medicines generated $5.34 billion in revenue, up 40.2% from fiscal 2024, its 5th consecutive year of revenue growth. Net income was $286.9 million, for a net margin of 5.4% versus a median of -123.9% in the prior 5 years. Gross margin was 87.5% (up from 84.4%) and operating margin 8.4%.

BeOne Medicines annual revenue, net income and EPS
Fiscal year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Revenue	$5.34B	$3.81B	$2.46B	$1.42B	$1.18B
Growth	+40.23%	+54.96%	+73.65%	+20.37%	+280.83%
Net income	$286.93M	$-644.79M	$-881.71M	$-2.00B	$-1.46B
EPS (diluted)	$0.19	$-0.47	$-0.65	$-1.49	$-1.21

Analyst forecast

Forecast

Consensus (28 analysts)

strong_buy

Avg. price target

$435.20+19.55%

Strong buy 7
Buy 20
Hold 1
Sell 0
Strong sell 0

Target range

Low $370.00High $528.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history

Next report: Nov 5, 2026
EPS estimate: $2.34
Last reported (Q2 2026): Aug 5, 2026
EPS actual vs est.: $0.16 vs —

ONC news

All ONC news

BeOne Medicines peers

Health Care sector

ONC peer companies
Company	Price	% Chg	Market cap	P/E	Compare
TEVATeva Pharmaceutical Industries Limited	39.18	+0.13%	$45.70B	65.3	vs ONC
RPRXRoyalty Pharma plc Class A	56.76	+0.57%	$32.80B	30.2	vs ONC
ALNYAlnylam Pharmaceuticals Inc.	224.41	+0.21%	$30.03B	37.8	vs ONC
ZTSZoetis Inc. Class A	71.55	+0.31%	$29.57B	11.8	vs ONC
ROIVRoivant Sciences Ltd.	34.75	-2.20%	$25.10B	—	vs ONC
TAKTakeda Pharmaceutical Company Limited ADR	18.37	+1.49%	$58.68B	—	vs ONC
UTHRUnited Therapeutics Corporation	545.00	+0.62%	$23.38B	19.5	vs ONC
GMABGenmab A/S ADS	36.65	-3.04%	$22.54B	29.6	vs ONC

Indexes, lists and sector

Largest Health Care stocks

BeOne Medicines stock FAQ

What is BeOne Medicines's stock price today?

ONC last traded at $364.02 as of Oct 7, 4:00 PM EDT, up 0.34% on the day. Prices are delayed at least 15 minutes.

When is BeOne Medicines's next earnings date?

BeOne Medicines is expected to report earnings on Thursday, November 5, 2026. Analysts expect EPS of $2.34.

What is ONC's P/E ratio?

ONC trades at a trailing P/E ratio of 65.12 and a forward P/E of 35.49, compared with a median of 29.9 for its closest peers.

Who is BeOne Medicines's CEO?

Mr. John V. Oyler is the chief executive officer of BeOne Medicines Ltd. ADR, which has about 12,000 employees.

What is the ONC 52-week high?

The 52-week high for ONC is $385.22 and the 52-week low is $253.95. The stock is currently 5.5% below its high.